Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon rece...
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor
About this item
Full title
Author / Creator
Kaye, Joel , Piryatinsky, Victor , Birnberg, Tal , Hingaly, Tal , Raymond, Emanuel , Kashi, Rina , Amit-Romach, Einat , Caballero, Ignacio S. , Towfic, Fadi , Ator, Mark A. , Rubinstein, Efrat , Laifenfeld, Daphna , Orbach, Aric , Shinar, Doron , Marantz, Yael , Grossman, Iris , Knappertz, Volker , Hayden, Michael R. and Laufer, Ralph
Publisher
United States: National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell populations, especially astrocytes and microglia....
Alternative Titles
Full title
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5068259
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5068259
Other Identifiers
ISSN
0027-8424
E-ISSN
1091-6490
DOI
10.1073/pnas.1607843113
